Latest University of Texas System Stories
Michael J. Wick, Ph.D., a recognized leader in the research of new anti-cancer drugs, has been named director of preclinical research at South Texas Accelerated Research Therapeutics (START). He will join the START team on Sept. 3. Dr. Wick comes to START from the Cancer Therapy & Research Center's (CTRC) Institute for Drug Development, where he was director of preclinical research. He is a recognized expert in the testing of novel therapies in animal models of human cancer. START, a...
SAN ANTONIO, July 20 /PRNewswire/ -- The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung. CTRC is one of only three sites in the United States, and the only in Texas, enrolling patients. The novel anti-cancer therapy, REOLYSIN(R), is a living virus, not a...
Language Access Network, Inc. (OTC:LANW), the leader in video interpretation services, announced today that Children's Medical Center Dallas, has installed and begun usage of the Company's MARTTI™ units. The Medical Center is a private, not-for-profit, and is one of the largest pediatric healthcare providers in the nation. Last year the medical center assisted more than 340,000 patients, and had 110,000 patient encounters for interpretation. Under the agreement, Language Access...
